Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.35 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.35 |
| ▸ | FPR2 | P25090 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15030294 | 0.84 | KDM4E (0.42) | ELANEKDM4EALDH1A1HDAC6KMT2A | |
| SCHEMBL8649103 | 0.83 | ELANE (0.51) | ELANEKDM4EALDH1A1KMT2APOLB | |
| Hydrochloric Acid SCHEMBL20944983 | 0.82 | ELANE (0.50) | ELANEKDM4EALDH1A1KMT2APOLB | |
| SCHEMBL8266056 | 0.81 | KDM4E (0.42) | KDM4EALDH1A1HDAC6KMT2APLA2G10 | |
| SCHEMBL3911656 | 0.81 | ALDH1A1 (0.50) | ELANEKDM4EALDH1A1MAPT | |
| SCHEMBL5122828 | 0.80 | HDAC6 (0.40) | ELANEKDM4EALDH1A1HDAC6KMT2A | |
| SCHEMBL8266745 | 0.79 | ALDH1A1 (0.58) | KDM4EALDH1A1HDAC6KMT2APOLB | |
| SCHEMBL761836 | 0.78 | ELANE (0.53) | ELANEKDM4EALDH1A1PARP1MAPT | |
| SCHEMBL8993820 | 0.78 | ELANE (0.52) | ELANEKDM4EALDH1A1HDAC6KMT2A | |
| SCHEMBL25938297 | 0.78 | ELANE (0.43) | ELANEKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434763-B2 | Derivatives of pyridinone as inhibitors for tissue transglutaminase | ZEDIRA GMBH (DE) | 2016-09-06 | — | — | US | disclosed |
| US-9434763-B2 | Derivatives of pyridinone as inhibitors for tissue transglutaminase | ZEDIRA GMBH (DE) | 2016-09-06 | — | — | US | disclosed |
| US-9434763-B2 | Derivatives of pyridinone as inhibitors for tissue transglutaminase | ZEDIRA GMBH (DE) | 2016-09-06 | — | — | US | disclosed |
| US-20150203535-A1 | DERIVATIVES OF PYRIDINONE AS INHIBITORS FOR TISSUE TRANSGLUTAMINASE | ZEDIRA GMBH (DE) | 2015-07-23 | — | — | US | disclosed |
| US-20150203535-A1 | DERIVATIVES OF PYRIDINONE AS INHIBITORS FOR TISSUE TRANSGLUTAMINASE | ZEDIRA GMBH (DE) | 2015-07-23 | — | — | US | disclosed |
| US-20150203535-A1 | DERIVATIVES OF PYRIDINONE AS INHIBITORS FOR TISSUE TRANSGLUTAMINASE | ZEDIRA GMBH (DE) | 2015-07-23 | — | — | US | disclosed |
| EP-2797892-B1 | PYRIDINONE DERIVATIVES AS TISSUE TRANSGLUTAMINASE INHIBITORS | ZEDIRA GMBH (DE) | 2015-05-27 | — | — | EP | disclosed |
| US-7402586-B2 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| US-7262211-B2 | Aromatic heterocyclic non-covalent inhibitors of urokinase and blood vessel formation | DENDREON CORPORATION (US) | 2007-08-28 | — | — | US | disclosed |
| EP-1036063-B1 | HETEROARYL AMINOGUANIDINES AND ALKOXYGUANIDINES AND THEIR USE AS PROTEASE INHIBITORS | ORTHO MCNEIL PHARM INC (US) | 2006-11-02 | — | — | EP | disclosed |
| WO-2003048127-A1 | AROMATIC HETEROCYCLIC NON-COVALENT INHIBITORS OF UROKINASE AND BLOOD VESSEL FORMATION | CORVAS INTERNATIONAL, INC. (US) | 2003-06-12 | — | — | WO | disclosed |
| US-6566379-B1 | As proteolytic enzyme inhibitors; thrombin inhibitors; for therapy of pancreatitis, thrombosis, ischemia, stroke, restenosis, emphysema or inflammation in a mammal | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-05-20 | — | — | US | disclosed |
| US-20030087921-A1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-05-08 | — | — | US | disclosed |
| US-6472399-B2 | ANTICOAGULANTS; MAY BE EMBEDDED IN OR PHYSICALLY LINKED TO MATERIALS USED IN MANUFACTURE OF DEVICES USED IN BLOOD COLLECTION, CIRCULATION, STENTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-10-29 | — | — | US | disclosed |
| US-20020086872-A1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | LU TIANBAO (US) | 2002-07-04 | — | — | US | disclosed |
| US-6350764-B2 | FOR INHIBITING LOSS OF BLOOD PLATELETS; INHIBITING FORMATION OF BLOOD PLATELET AGGREGATES, FIBRIN, THROMBUS, AND EMBOLUS; ANTICOAGULANTS EMBEDDED IN DEVICES FOR BLOOD COLLECTION, CIRCULATION, STORAGE (CATHETERS, DIALYSIS MACHINES); STENTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-02-26 | — | — | US | disclosed |
| US-20020007070-A1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | LU TIANBAO (US) | 2002-01-17 | — | — | US | disclosed |
| US-6245763-B1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-06-12 | — | — | US | disclosed |
| CN-1283189-A | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | DIMENSIONAL PHARM INC (US) | 2001-02-07 | — | — | CN | disclosed |
| US-6037356-A | ANTICOAGULANTS; ANTIINFLAMMATORY AND ANTIARTHRITIC AGENTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203535-A1 | DERIVATIVES OF PYRIDINONE AS INHIBITORS FOR TISSUE TRANSGLUTAMINASE | PLPBP, PNPO, PDXK | ELANE 2984/4885KDM4E 1470/4885ALDH1A1 787/4885 |
| US-20020086872-A1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | F9, PLG, MMP9 | ELANE 323/4885KDM4E 2326/4885ALDH1A1 3065/4885 |
| US-20020007070-A1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | F9, PLG, PLAT | ELANE 304/4885KDM4E 2228/4885ALDH1A1 3012/4885 |
| US-20030087921-A1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | F9, PLG, F2R | ELANE 291/4885KDM4E 2269/4885ALDH1A1 3022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.